VANGUARD GROUP INC - ALLOGENE THERAPEUTICS INC ownership

ALLOGENE THERAPEUTICS INC's ticker is ALLO and the CUSIP is 019770106. A total of 164 filers reported holding ALLOGENE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 2.03 and the average weighting 0.2%.

Quarter-by-quarter ownership
VANGUARD GROUP INC ownership history of ALLOGENE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$33,563,338
-10.0%
10,587,804
+41.1%
0.00%0.0%
Q2 2023$37,282,420
+3.3%
7,501,493
+2.7%
0.00%0.0%
Q1 2023$36,088,360
-21.0%
7,305,336
+0.6%
0.00%0.0%
Q4 2022$45,698,239
-40.9%
7,265,221
+1.4%
0.00%
-50.0%
Q3 2022$77,362,000
-19.3%
7,163,082
-14.8%
0.00%
-33.3%
Q2 2022$95,830,000
+55.7%
8,406,147
+24.5%
0.00%
+200.0%
Q1 2022$61,529,000
-38.8%
6,753,980
+0.2%
0.00%
-50.0%
Q4 2021$100,588,000
-41.5%
6,741,839
+0.7%
0.00%
-50.0%
Q3 2021$172,080,000
-0.1%
6,695,720
+1.4%
0.00%0.0%
Q2 2021$172,189,000
-18.1%
6,602,306
+10.8%
0.00%
-33.3%
Q1 2021$210,271,000
+44.0%
5,956,693
+2.9%
0.01%
+50.0%
Q4 2020$146,051,000
-31.5%
5,786,477
+2.3%
0.00%
-42.9%
Q3 2020$213,333,000
-15.3%
5,657,203
-3.8%
0.01%
-22.2%
Q2 2020$251,839,000
+216.0%
5,881,314
+43.5%
0.01%
+200.0%
Q1 2020$79,694,000
-22.3%
4,099,451
+3.8%
0.00%0.0%
Q4 2019$102,577,000
-4.7%
3,948,293
+0.0%
0.00%
-25.0%
Q3 2019$107,597,000
+16.4%
3,947,770
+14.7%
0.00%
+33.3%
Q2 2019$92,449,000
+52.3%
3,443,180
+64.0%
0.00%
+50.0%
Q1 2019$60,703,000
+10.2%
2,099,721
+2.6%
0.00%0.0%
Q4 2018$55,107,0002,046,3290.00%
Other shareholders
ALLOGENE THERAPEUTICS INC shareholders Q4 2020
NameSharesValueWeighting ↓
Vida Ventures Advisors, LLC 1,798,163$16,381,0009.53%
Wildcat Capital Management, LLC 2,128,370$19,389,0004.96%
TPG GP A, LLC 18,716,306$170,506,0002.11%
Pier Capital, LLC 746,669$6,802,0000.87%
Coastal Bridge Advisors, LLC 401,929$3,662,0000.84%
HARBOR CAPITAL ADVISORS, INC. 92,755$845,0000.40%
Lombard Odier Asset Management (Switzerland) SA 501,219$4,566,0000.36%
Navalign, LLC 74,271$623,0000.26%
PDT Partners, LLC 241,592$2,201,0000.19%
GSA CAPITAL PARTNERS LLP 148,804$1,356,0000.18%
View complete list of ALLOGENE THERAPEUTICS INC shareholders